A01K 2207/10
Animals modified by protein administration, for non-therapeutic purpose
A01K2207/10 (Animals modified by protein administration, for non-therapeutic purpose) appears on 40 US grants and 118 published applications in this corpus.
Search patents in A01K- Granted patents
- 40
- Published applications
- 118
- Assignees
- 86
- Inventors
- 282
- Latest grant
- 3 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 2 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 2 |
| 2008 | 0 | 4 |
| 2009 | 0 | 3 |
| 2010 | 1 | 6 |
| 2011 | 3 | 4 |
| 2012 | 2 | 1 |
| 2013 | 1 | 3 |
| 2014 | 2 | 2 |
| 2015 | 1 | 8 |
| 2016 | 2 | 6 |
| 2017 | 2 | 7 |
| 2018 | 1 | 5 |
| 2019 | 1 | 8 |
| 2020 | 3 | 11 |
| 2021 | 5 | 9 |
| 2022 | 1 | 10 |
| 2023 | 3 | 5 |
| 2024 | 7 | 5 |
| 2025 | 4 | 9 |
| 2026 | 1 | 8 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods of producing granulomas and animal models of sarcoidosis3 Mar 2026US 12,564,179 B2The United States Government as represented by the Department of Veterans Affairs
- Composition comprising MLS-STAT3 for prevention or treatment of immune disease9 Dec 2025US 12,492,233 B2The Catholic University of Korea Industry-Academic Cooperation Foundation
- CRISPR having or associated with destabilization domains7 Oct 2025US 12,435,320 B2Massachusetts Institute of Technology
- Anti-elastin antibodies and methods of use29 Jul 2025US 12,371,479 B2Clemson University Research Foundation
- Methods of reducing FUS/TLS- or TDP-43-mediated neuronal cytotoxicity in amyotrophic lateral sclerosis (ALS) by UPF215 Apr 2025US 12,275,764 B2Brandeis University
- Animal models, screening methods, and treatment methods for intraocular diseases or disorders24 Sep 2026US 2026/0283123 A1Smilebiotek Zhuhai Limited
- Animal models, screening methods, and treatment methods for intraocular diseases or disorders17 Sep 2026US 2026/0271895 A1Smilebiotek Zhuhai Limited
- Method for Treating Ulcerative Colitis or Primary Sclerosing Cholangitis16 Jul 2026US 2026/0199576 A1Kyoto University
- Crispr having or associated with destabilization domains4 Jun 2026US 2026/0152731 A1Massachusetts Institute of Technology
- Gene therapy30 Apr 2026US 2026/0115317 A1
Most cited
By later US patents
- Long term disease modification using immunostimulatory oligonucleotides7US 8,815,817 B2Dynavax Technologies Corporation · 2014
- Multiplexed genome editing6US 10,959,413 B2President and Fellows of Harvard College · 2021
- Multiplexed genome editing5US 10,375,938 B2President and Fellows of Harvard College · 2019
- Animal models for evaluating pharmaceutical compounds3US 10,729,791 B2Imcyse SA · 2020
- Multiplexed genome editing3US 10,925,263 B2President and Fellows of Harvard College · 2021